Page last updated: 2024-10-22

albuterol and Infant, Premature, Diseases

albuterol has been researched along with Infant, Premature, Diseases in 14 studies

Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Infant, Premature, Diseases: Diseases that occur in PREMATURE INFANTS.

Research Excerpts

ExcerptRelevanceReference
"Seven infants had acute renal failure, two had persistent metabolic acidosis without renal failure and the remaining infant had a combination of acute renal failure and persistent metabolic acidosis."1.28Salbutamol infusion to treat neonatal hyperkalaemia. ( Brooker, R; Emery, EF; Gamsu, HR; Greenough, A, 1992)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (35.71)18.2507
2000's6 (42.86)29.6817
2010's3 (21.43)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ng, G2
da Silva, O2
Ohlsson, A4
Vemgal, P2
Mildenberger, E1
Versmold, HT1
Thomas, MR1
Rafferty, GF1
Blowes, R1
Peacock, JL1
Marlow, N1
Calvert, S1
Milner, A1
Greenough, A3
O'Hare, FM1
Molloy, EJ1
Yaseen, H1
Khalaf, M1
Dana, A1
Yaseen, N1
Darwich, M1
Derish, M1
Hodge, G1
Dunn, C1
Ariagno, R1
Denjean, A1
Paris-Llado, J1
Zupan, V1
Debillon, T1
Kieffer, F1
Magny, JF1
Desfrères, L1
Llanas, B1
Guimaraes, H1
Moriette, G1
Voyer, M1
Dehan, M1
Breart, G1
Sivakumar, D1
Bosque, E1
Goldman, SL1
Khalaf, MN1
Hurley, JF1
Bhandari, V1
Emery, EF1
Brooker, R1
Gamsu, HR1
Yuksel, B1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Albuterol Dose-Response on Pulmonary Function Testing in Preterm Infants at Risk of Bronchopulmonary Dysplasia[NCT02447250]Phase 414 participants (Actual)Interventional2013-10-24Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Association of Smoke Exposure During Pregnancy and Neonatal Response to Albuterol

Mothers who smoked cigarettes during pregnancy and the rate of albuterol response of their infants (NCT02447250)
Timeframe: Smoking and second hand smoke exposure history will be obtained at enrollment. Albuterol response will be obtained within one week.

Interventionparticipants (Number)
albuterol responders of mothers who smokedalbuterol responders of non-smoker mothers %
Single Arm: Varied Albuterol Dose Response46

Birth Weight of Albuterol Responders vs Non Responders

birth weight in grams of each subject was recorded at time of enrollment (NCT02447250)
Timeframe: within one week of entering study

Interventiongrams (Mean)
albuterol respondersalbuterol non responders
Single Arm: Varied Albuterol Dose Response847.21147.7

Change in Respiratory Resistance

The primary outcome is the percentage of subjects who show a positive response to each dose of albuterol. A positive response is defined as a greater than or equal to 10% decrease in respiratory resistance (Rrs). The change in RRs was measured at baseline and again after each dose of albuterol. All measurements were taken within a 7 day time frame for each subject such that each subject would have up to 3 results measured during a 7 day period, if he/she were able to complete three sets of PFTs according to study protocol. The change in Rrs was calculated by subtracting the baseline Rrs from the post-albuterol Rrs. (NCT02447250)
Timeframe: Within one week of performing pulmonary function tests

Interventioncm h2o/mL/sec (Mean)
dose 1dose 2dose 3
Single Arm: Varied Albuterol Dose Response0.0110.0060.014

Etiology of Preterm Delivery

Reason for each subject's preterm delivery was classified as either preterm labor or delivery for maternal indications (eg pre-eclampsia). (NCT02447250)
Timeframe: within one week of entering study

InterventionParticipants (Count of Participants)
preterm labor, responsive to albuterolmaternal indicated delivery, responsive to albuter
Single Arm: Varied Albuterol Dose Response46

Family History of Asthma and Likelihood to Respond to Albuterol

Family history was obtained from verbal history by subject's mother at time of enrollment in study. A positive family history was noted if a first degree relative of the subject (infant) had a diagnosis of asthma. (NCT02447250)
Timeframe: History collected at enrollment, albuterol response assessed within one week

Interventionparticipants (Number)
family hx of asthma, respond to albuterolno fam hx asthma, respond to albuterol
Single Arm: Varied Albuterol Dose Response19

Gestational Age at Birth

Average gestational age (GA) in weeks at birth for subjects who responded to albuterol versus subjects without a positive response (NCT02447250)
Timeframe: within one week of entering study

Interventionweeks (Mean)
birth GA albuterol responders, weeksbirth GA albuterol non responders
Single Arm: Varied Albuterol Dose Response26.728.5

Maternal BMI at Time of Pregnancy and Likelihood of Positive Response to Albuterol

Maternal BMI will be obtained from her medial record, and she will be asked about weight gain during pregnancy at time of enrollment. Results will be compared for infants born to women with a normal BMI vs. those with obese BMI (>30). (NCT02447250)
Timeframe: Maternal information collected at enrollment; albuterol response assessed within one week

Interventionkg/m^2 (Mean)
mean BMI mothers of albuterol-responders , any dosmean BMI mothers of albuterol non-responders
Single Arm: Varied Albuterol Dose Response27.427.3

Number of Participants With Positive Response at Different Albuterol Doses

Compare number of subjects who have a positive response (greater than or equal to 10% decrease in respiratory resistance) to each dose of albuterol (NCT02447250)
Timeframe: Data collected 15 minutes after dose in each session. Study includes 3 sessions within a 7 day period.

Interventionparticipants (Number)
positive Rrs response at 180 mcg albuterolpositive Rrs response at 270 mcg albuterolpositive Rrs response at 360 mcg albuterol
Single Arm: Varied Albuterol Dose Response644

Reviews

6 reviews available for albuterol and Infant, Premature, Diseases

ArticleYear
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.
    The Cochrane database of systematic reviews, 2016, 12-14, Volume: 12

    Topics: Albuterol; Aminophylline; Beclomethasone; Bronchodilator Agents; Chronic Disease; Drug Therapy, Comb

2016
Interventions for non-oliguric hyperkalaemia in preterm neonates.
    The Cochrane database of systematic reviews, 2012, May-16, Issue:5

    Topics: Albuterol; Glucose; Humans; Hyperkalemia; Infant, Newborn; Infant, Premature; Infant, Premature, Dis

2012
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.
    The Cochrane database of systematic reviews, 2012, Jun-13, Issue:6

    Topics: Albuterol; Beclomethasone; Bronchodilator Agents; Chronic Disease; Humans; Infant, Newborn; Infant,

2012
Pathogenesis and therapy of non-oliguric hyperkalaemia of the premature infant.
    European journal of pediatrics, 2002, Volume: 161, Issue:8

    Topics: Adrenergic beta-Agonists; Albuterol; Calcium; Diuretics; Evidence-Based Medicine; Exchange Transfusi

2002
Interventions for non-oliguric hyperkalaemia in preterm neonates.
    The Cochrane database of systematic reviews, 2007, Jan-24, Issue:1

    Topics: Albuterol; Glucose; Humans; Hyperkalemia; Infant, Newborn; Infant, Premature; Infant, Premature, Dis

2007
What is the best treatment for hyperkalaemia in a preterm infant?
    Archives of disease in childhood, 2008, Volume: 93, Issue:2

    Topics: Albuterol; Calcium Gluconate; Evidence-Based Medicine; Exchange Transfusion, Whole Blood; Humans; Hy

2008

Trials

4 trials available for albuterol and Infant, Premature, Diseases

ArticleYear
Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double-blind study.
    European journal of pediatrics, 1998, Volume: 157, Issue:11

    Topics: Administration, Inhalation; Albuterol; Beclomethasone; Bronchodilator Agents; Bronchopulmonary Dyspl

1998
Bronchodilator delivered by metered dose inhaler and spacer improves respiratory system compliance more than nebulizer-delivered bronchodilator in ventilated premature infants.
    Pediatric pulmonology, 1999, Volume: 27, Issue:3

    Topics: Administration, Inhalation; Albuterol; Analysis of Variance; Bronchodilator Agents; Cross-Over Studi

1999
A prospective controlled trial of albuterol aerosol delivered via metered dose inhaler-spacer device (MDI) versus jet nebulizer in ventilated preterm neonates.
    American journal of perinatology, 2001, Volume: 18, Issue:3

    Topics: Administration, Inhalation; Albuterol; Bronchodilator Agents; Humans; Infant, Newborn; Infant, Prema

2001
Effect of nebulized salbutamol in preterm infants during the first year of life.
    The European respiratory journal, 1991, Volume: 4, Issue:9

    Topics: Aerosols; Albuterol; Cough; Female; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Lu

1991

Other Studies

4 other studies available for albuterol and Infant, Premature, Diseases

ArticleYear
Plethysmograph and interrupter resistance measurements in prematurely born young children.
    Archives of disease in childhood. Fetal and neonatal edition, 2006, Volume: 91, Issue:3

    Topics: Airway Obstruction; Airway Resistance; Albuterol; Bronchodilator Agents; Functional Residual Capacit

2006
Salbutamol versus cation-exchange resin (kayexalate) for the treatment of nonoliguric hyperkalemia in preterm infants.
    American journal of perinatology, 2008, Volume: 25, Issue:3

    Topics: Adrenergic beta-Agonists; Albuterol; Cation Exchange Resins; Female; Humans; Hyperkalemia; Infant, N

2008
Aerosolized albuterol improves airway reactivity in infants with acute respiratory failure from respiratory syncytial virus.
    Pediatric pulmonology, 1998, Volume: 26, Issue:1

    Topics: Acute Disease; Adrenergic beta-Agonists; Aerosols; Albuterol; Functional Residual Capacity; Humans;

1998
Salbutamol infusion to treat neonatal hyperkalaemia.
    Journal of perinatal medicine, 1992, Volume: 20, Issue:6

    Topics: Acidosis; Acute Kidney Injury; Albuterol; Female; Humans; Hyperkalemia; Infant, Low Birth Weight; In

1992